Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level , Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023 --... -Today at 07:03 am- MarketScreener
Anand Jeyasekharan Kimr Tsuchimoto Promisingpreclinicaldataignitefurther Research Radiopharma Program Advancing Toward Northstar Medical Radioisotopes Cancer Science Institute
Source: marketscreener.com